Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT05999994
- Locations
- 🇧🇪
UCL- Saint Luc, Bruxelles, Belgium
🇫🇷Institut Curie, Paris, France
🇳🇱Prinses Maxima Centrum, Utrecht, Netherlands
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT05999968
- Locations
- 🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Comunidad De, Spain
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇩🇪Studienpraxis Urologie, Nürtingen, Baden-Württemberg, Germany
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10000
- Registration Number
- NCT05986292
- Locations
- 🇺🇸
CMR of Greater New Haven, Hamden, Connecticut, United States
🇺🇸Clinical Research of South Florida, Coral Gables, Florida, United States
🇺🇸Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida, United States
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT05978713
- Locations
- 🇺🇸
Las Vegas Clinical Research Unit - PPD, Las Vegas, Nevada, United States
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 520
- Registration Number
- NCT05971940
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC, Norman, Oklahoma, United States
🇲🇽Salud Cardiovascular, Guadalajara, Jalisco, Mexico
🇮🇳BSES MG Hospital, Mumbai, Maharashtra, India
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 168
- Registration Number
- NCT05963022
- Locations
- 🇨🇳
Dalian University - The Affiliated Zhongshan Hospital, Dalian, Liaoning, China
🇨🇳Pudong New Area People's Hospital Shanghai, Shanghai, Shanghai, China
🇨🇳Jiangxi Pingxiang People's Hospital, Pingxiang, Jiangxi, China
A Study of LY3871801 in Healthy Asian and Non-Asian Participants
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05960851
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 85
- Registration Number
- NCT05959096
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Daytona Beach, Florida, United States
A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 57
- Registration Number
- NCT05959109
- Locations
- 🇺🇸
LabCorp CRU, Inc., Dallas, Texas, United States
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT05936151
- Locations
- 🇺🇸
Prime Health and Wellness/SKYCRNG, Fayette, Mississippi, United States
🇺🇸The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸Care Access - 801 South Power Road, Mesa, Mesa, Arizona, United States